Eliem Therapeutics, Inc.

As of May 12, 2025, Eliem Therapeutics, Inc. shows a mildly bearish trend, with daily moving averages and weekly Bollinger Bands indicating bearish momentum, despite some mildly bullish signals from weekly MACD and KST.

Eliem Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $21 million and a market cap of $81.09 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a debt-to-equity ratio of -0.51.

As of Jun 18, Eliem Therapeutics, Inc. has a market capitalization of 81.09 million, with net sales of 0.00 million and a net profit of -92.98 million over the last four quarters. The company reported shareholder's funds of 211.88 million and total assets of 217.19 million as of Dec 24.